{"title":"弥合注射和手术之间的差距:膝关节骨关节炎膝动脉栓塞的荟萃分析。","authors":"Rada Abussa, Aleksandar Jeremic","doi":"10.1016/j.acra.2025.05.011","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale and objectives: </strong>To evaluate the clinical efficacy and safety of genicular artery embolization (GAE) for chronic knee osteoarthritis (OA), incorporating recent trials and long-term outcomes.</p><p><strong>Materials and methods: </strong>A systematic review identified peer-reviewed studies of GAE in knee OA, including randomized controlled trials (RCTs) and prospective series. Data on pain scores, function, follow-up, and adverse events were extracted. Pooled pain reductions (VAS, WOMAC) were analyzed using random-effects models. Forest and funnel plots visualized treatment effects and publication bias.</p><p><strong>Results: </strong>Fourteen studies (510 patients, 567 knees) met inclusion criteria, including three sham-controlled RCTs and several prospective series. GAE consistently reduced pain in open-label studies, with a pooled pre-post pain reduction of ∼30 points (0-100 scale) at 6-12 months. Functional scores (WOMAC, KOOS) also improved. About 78-92% of patients achieved clinically meaningful improvement (≥50% pain reduction or ≥10-15 point change) by 12 months. However, sham-controlled RCTs yielded mixed results: one showed early benefit, while two found no significant difference versus placebo at 4-12 months. Heterogeneity was moderate (I² ∼74%). Minor adverse events included transient skin discoloration (∼10-30%) and groin hematoma (∼2-3%). One case of vasculitis and one deep vein thrombosis were reported; no major complications occurred.</p><p><strong>Conclusion: </strong>GAE appears effective and safe for chronic knee OA, though its benefit over placebo remains uncertain. This meta-analysis, incorporating recent evidence and 2-year data, underscores GAE's promise-but highlights the need for larger, rigorously designed RCTs to confirm efficacy, refine patient selection, optimize techniques, and guide clinical use.</p>","PeriodicalId":50928,"journal":{"name":"Academic Radiology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bridging the Gap between Injections and Surgery: Meta-Analysis of Genicular Artery Embolization in Knee Osteoarthritis.\",\"authors\":\"Rada Abussa, Aleksandar Jeremic\",\"doi\":\"10.1016/j.acra.2025.05.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Rationale and objectives: </strong>To evaluate the clinical efficacy and safety of genicular artery embolization (GAE) for chronic knee osteoarthritis (OA), incorporating recent trials and long-term outcomes.</p><p><strong>Materials and methods: </strong>A systematic review identified peer-reviewed studies of GAE in knee OA, including randomized controlled trials (RCTs) and prospective series. Data on pain scores, function, follow-up, and adverse events were extracted. Pooled pain reductions (VAS, WOMAC) were analyzed using random-effects models. Forest and funnel plots visualized treatment effects and publication bias.</p><p><strong>Results: </strong>Fourteen studies (510 patients, 567 knees) met inclusion criteria, including three sham-controlled RCTs and several prospective series. GAE consistently reduced pain in open-label studies, with a pooled pre-post pain reduction of ∼30 points (0-100 scale) at 6-12 months. Functional scores (WOMAC, KOOS) also improved. About 78-92% of patients achieved clinically meaningful improvement (≥50% pain reduction or ≥10-15 point change) by 12 months. However, sham-controlled RCTs yielded mixed results: one showed early benefit, while two found no significant difference versus placebo at 4-12 months. Heterogeneity was moderate (I² ∼74%). Minor adverse events included transient skin discoloration (∼10-30%) and groin hematoma (∼2-3%). One case of vasculitis and one deep vein thrombosis were reported; no major complications occurred.</p><p><strong>Conclusion: </strong>GAE appears effective and safe for chronic knee OA, though its benefit over placebo remains uncertain. This meta-analysis, incorporating recent evidence and 2-year data, underscores GAE's promise-but highlights the need for larger, rigorously designed RCTs to confirm efficacy, refine patient selection, optimize techniques, and guide clinical use.</p>\",\"PeriodicalId\":50928,\"journal\":{\"name\":\"Academic Radiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-05-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Academic Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.acra.2025.05.011\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Academic Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.acra.2025.05.011","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Bridging the Gap between Injections and Surgery: Meta-Analysis of Genicular Artery Embolization in Knee Osteoarthritis.
Rationale and objectives: To evaluate the clinical efficacy and safety of genicular artery embolization (GAE) for chronic knee osteoarthritis (OA), incorporating recent trials and long-term outcomes.
Materials and methods: A systematic review identified peer-reviewed studies of GAE in knee OA, including randomized controlled trials (RCTs) and prospective series. Data on pain scores, function, follow-up, and adverse events were extracted. Pooled pain reductions (VAS, WOMAC) were analyzed using random-effects models. Forest and funnel plots visualized treatment effects and publication bias.
Results: Fourteen studies (510 patients, 567 knees) met inclusion criteria, including three sham-controlled RCTs and several prospective series. GAE consistently reduced pain in open-label studies, with a pooled pre-post pain reduction of ∼30 points (0-100 scale) at 6-12 months. Functional scores (WOMAC, KOOS) also improved. About 78-92% of patients achieved clinically meaningful improvement (≥50% pain reduction or ≥10-15 point change) by 12 months. However, sham-controlled RCTs yielded mixed results: one showed early benefit, while two found no significant difference versus placebo at 4-12 months. Heterogeneity was moderate (I² ∼74%). Minor adverse events included transient skin discoloration (∼10-30%) and groin hematoma (∼2-3%). One case of vasculitis and one deep vein thrombosis were reported; no major complications occurred.
Conclusion: GAE appears effective and safe for chronic knee OA, though its benefit over placebo remains uncertain. This meta-analysis, incorporating recent evidence and 2-year data, underscores GAE's promise-but highlights the need for larger, rigorously designed RCTs to confirm efficacy, refine patient selection, optimize techniques, and guide clinical use.
期刊介绍:
Academic Radiology publishes original reports of clinical and laboratory investigations in diagnostic imaging, the diagnostic use of radioactive isotopes, computed tomography, positron emission tomography, magnetic resonance imaging, ultrasound, digital subtraction angiography, image-guided interventions and related techniques. It also includes brief technical reports describing original observations, techniques, and instrumental developments; state-of-the-art reports on clinical issues, new technology and other topics of current medical importance; meta-analyses; scientific studies and opinions on radiologic education; and letters to the Editor.